Anticipation of Amylyx PBH Phase 3 data lifts Vogenx

 

 $VOGX +67% in premarket

• VOGX develops mizagliflozin (oral SGLT1 inhibitor) for post-bariatric hypoglycemia (PBH), same indication as Amylyx's avexitide (GLP-1 antagonist).
• Amylyx (AMLX) expected to report topline Phase 3 LUCIDITY trial data for avexitide in PBH on/around Aug 18.
• No approved therapies exist for PBH; positive AMLX data would validate the therapeutic area and potentially lift peers.
• VOGX, a recent IPO (priced $13 on Aug 11, began trading Aug 12), has ~$200M market cap, making it a leveraged retail sympathy play.
• Stock closed Aug 17 at $15.75 (up 6.56%); prior after-hours surge continued into Aug 18 premarket.
• No new Vogenx-specific news or PR; move driven by sector momentum and binary event anticipation per trading chatter and reports.

https://finviz.com/stock?t=VOGX&p=d